Exploring Sex Differences in Outcomes of Dual Antiplatelet Therapy for Patients With Noncardioembolic Mild-to-Moderate Ischemic Stroke or High-Risk Transient Ischemic Attack: A Propensity-Matched Analysis of the READAPT Study Cohort
Matteo Foschi,Lucio D'Anna,Eleonora De Matteis,Federico De Santis,Michele Romoli,Tiziana Tassinari,Valentina Saia,Silvia Cenciarelli,Chiara Bedetti,Chiara Padiglioni,Bruno Censori,Valentina Puglisi,Luisa Vinciguerra,Maria Guarino,Valentina Barone,Marialuisa Zedde,Ilaria Grisendi,Marina Diomedi,Maria Rosaria Bagnato,Marco Petruzzellis,Domenico Maria Mezzapesa,Pietro Di Viesti,Vincenzo Inchingolo,Manuel Cappellari,Cecilia Zivelonghi,Paolo Candelaresi,Vincenzo Andreone,Giuseppe Rinaldi,Alessandra Bavaro,Anna Cavallini,Stefan Moraru,Maria Grazia Piscaglia,Valeria Terruso,Marina Mannino,Alessandro Pezzini,Giovanni Frisullo,Francesco Muscia,Maurizio Paciaroni,Maria Giulia Mosconi,Andrea Zini,Ruggiero Leone,Carmela Palmieri,Letizia Maria Cupini,Michela Marcon,Rossana Tassi,Enzo Sanzaro,Giuli Papiri,Cristina Paci,Giovanna Viticchi,Daniele Orsucci,Anne Falcou,Simone Beretta,Roberto Tarletti,Patrizia Nencini,Eugenia Rota,Federica Nicoletta Sepe,Delfina Ferrandi,Luigi Caputi,Gino Volpi,Salvatore La Spada,Mario Beccia,Claudia Rinaldi,Vincenzo Mastrangelo,Francesco Di Blasio,Paolo Invernizzi,Giuseppe Pelliccioni,Maria Vittoria De Angelis,Laura Bonanni,Giampietro Ruzza,Emanuele Alessandro Caggia,Monia Russo,Agnese Tonon,Maria Cristina Acciarri,Sabrina Anticoli,Cinzia Roberti,Giovanni Manobianca,Gaspare Scaglione,Francesca Pistoia,Alberto Fortini,Antonella De Boni,Alessandra Sanna,Alberto Chiti,Leonardo Barbarini,Marcella Caggiula,Maela Masato,Massimo Del Sette,Francesco Passarelli,Maria Roberta Bongioanni,Manuela De Michele,Stefano Ricci,Raffaele Ornello,Simona Sacco,Martina Valente,Silvia Paolucci,Leonardo Biscetti,Valentina Cameriere,Eleonora Ponente,Martina Caccamo,Debora Galotto,Sergio Altomare,Maurizio Giorelli,Federica Naldi,Chiara Bassi,Claudia Faini,Paola Ajdinaj,Anna di Giovanni,Elisa Sacchini,Antonio Zito,Alessia Giossi,Patrizio Cardinali,Stefania Maria Angelocola,Laura Tudisco,Maraia Cristina Baruffi,Alessandro Canessa,Davide Sassos,Maria Grazia Vittorini,Serena Gallo Cassarino,Gloria Valcamonica,Annalisa Rizzo,Marco Vista,Elisabetta Menegazzo,Susanna Diamanti,Carlo Ferrarese,Antonio De Mase,Emanuele Spina,Thomas Fleetwood,Gian Luca Bruzzone,Antonio Genovese,Daniela Monaco,Pierluigi Tocco,Chiara Menichetti,Federica Letteri,Serena Nannucci,Rosario Pascarella,Federica Assenza,Enrico Maria Lotti,Giorgia Bernabè,Filomena Di Lisi,Ilaria Maestrini,Novella Bonaffini,Maria Chiara Ricciardi,Chiara De Fino,Nicoletta Giuseppa Caracciolo,Manuela De Michele,Irene Scala,Simone Bellavia,Cristina Paci,Emanuele Puca,Giovanni Matteo Fratta,Ivo Giuseppe,De Franco Maurizio Acampa,Roberto Cappellani,Eleonora Sgarlata,Mara Zenorini,Cristina De Luca,Francesco Perini
DOI: https://doi.org/10.1161/strokeaha.124.049210
IF: 10.17
2024-12-11
Stroke
Abstract:Stroke, Ahead of Print. BACKGROUND:Sex may impact clinical outcomes in patients with stroke treated with dual antiplatelet therapy (DAPT). We aimed to investigate the sex differences in the short-term outcomes of DAPT within a real-world population of patients with noncardioembolic mild-to-moderate ischemic stroke or high-risk transient ischemic attack.METHODS:We performed a propensity score–matched analysis from a prospective multicentric cohort study (READAPT [Real-Life Study on Short-Term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack]) by including patients with noncardioembolic mild-to-moderate stroke (National Institutes of Health Stroke Scale score of 0–10) or high-risk transient ischemic attack (age, blood pressure, clinical features, duration of transient ischemic attack, presence of diabetes [ABCD2] ≥4) who initiated DAPT within 48 hours of symptom onset. The primary effectiveness outcome was the 90-day risk of new ischemic stroke or other vascular events. The secondary effectiveness outcomes were the 90-day modified Rankin Scale score ordinal shift, vascular and all-cause mortality, and 24-hour early neurological improvement or deterioration. The safety outcomes included the 90-day risk of moderate-to-severe and any bleeding, symptomatic intracranial hemorrhage, and 24-hour hemorrhagic transformation. Outcomes were compared between sexes using Cox and generalized ordinal logistic regression analyses, along with calculating risk differences and ratios.RESULTS:From 2278 patients in the READAPT study cohort, we included 1643 mild-to-moderate strokes or high-risk transient ischemic attacks treated with DAPT (mean age, 69.8±12.0 years; 34.3% women). We matched 531 women and men. The 90-day risk of new ischemic stroke or other vascular events was significantly lower among women than men (hazard ratio, 0.53 [95% CI, 0.28–0.99];P=0.039). There were no significant differences in secondary effectiveness outcomes. The 90-day risk of safety outcomes was extremely low and did not differ between women and men (moderate-to-severe bleedings: 0.4% versus 0.8%;P=0.413; symptomatic intracranial hemorrhage: 0.2% versus 0.4%;P=0.563). Subgroup analysis for primary effectiveness outcome showed a lower 90-day risk of new ischemic stroke or other vascular events among women aged <50 years, baseline National Institutes of Health Stroke Scale score of 0 to 5, prestroke modified Rankin Scale score <2, large artery atherosclerosis cause, and no diabetes.CONCLUSIONS:Our findings suggest that women with noncardioembolic mild-to-moderate stroke or high-risk transient ischemic attack treated with DAPT may have lower short-term risk of recurrent ischemic events than men. Further research is needed to understand the mechanisms behind potential sex-based differences in outcomes after DAPT use.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT05476081.
peripheral vascular disease,clinical neurology